Cargando…
Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5809482/ https://www.ncbi.nlm.nih.gov/pubmed/29434192 http://dx.doi.org/10.1038/s41408-018-0055-x |
| _version_ | 1783299569205903360 |
|---|---|
| author | Kater, Arnon P. Tonino, Sanne H. Spiering, Marjolein Chamuleau, Martine E. D. Liu, Roberto Adewoye, Adeboye Henry Gao, Jie Dreiling, Lyndah Xin, Yan Doorduijn, Jeanette K. Kersten, Marie José |
| author_facet | Kater, Arnon P. Tonino, Sanne H. Spiering, Marjolein Chamuleau, Martine E. D. Liu, Roberto Adewoye, Adeboye Henry Gao, Jie Dreiling, Lyndah Xin, Yan Doorduijn, Jeanette K. Kersten, Marie José |
| author_sort | Kater, Arnon P. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-5809482 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2018 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-58094822018-02-28 Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies Kater, Arnon P. Tonino, Sanne H. Spiering, Marjolein Chamuleau, Martine E. D. Liu, Roberto Adewoye, Adeboye Henry Gao, Jie Dreiling, Lyndah Xin, Yan Doorduijn, Jeanette K. Kersten, Marie José Blood Cancer J Correspondence Nature Publishing Group UK 2018-02-12 /pmc/articles/PMC5809482/ /pubmed/29434192 http://dx.doi.org/10.1038/s41408-018-0055-x Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
| spellingShingle | Correspondence Kater, Arnon P. Tonino, Sanne H. Spiering, Marjolein Chamuleau, Martine E. D. Liu, Roberto Adewoye, Adeboye Henry Gao, Jie Dreiling, Lyndah Xin, Yan Doorduijn, Jeanette K. Kersten, Marie José Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies |
| title | Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies |
| title_full | Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies |
| title_fullStr | Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies |
| title_full_unstemmed | Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies |
| title_short | Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies |
| title_sort | final results of a phase 1b study of the safety and efficacy of the pi3kδ inhibitor acalisib (gs-9820) in relapsed/refractory lymphoid malignancies |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5809482/ https://www.ncbi.nlm.nih.gov/pubmed/29434192 http://dx.doi.org/10.1038/s41408-018-0055-x |
| work_keys_str_mv | AT katerarnonp finalresultsofaphase1bstudyofthesafetyandefficacyofthepi3kdinhibitoracalisibgs9820inrelapsedrefractorylymphoidmalignancies AT toninosanneh finalresultsofaphase1bstudyofthesafetyandefficacyofthepi3kdinhibitoracalisibgs9820inrelapsedrefractorylymphoidmalignancies AT spieringmarjolein finalresultsofaphase1bstudyofthesafetyandefficacyofthepi3kdinhibitoracalisibgs9820inrelapsedrefractorylymphoidmalignancies AT chamuleaumartineed finalresultsofaphase1bstudyofthesafetyandefficacyofthepi3kdinhibitoracalisibgs9820inrelapsedrefractorylymphoidmalignancies AT liuroberto finalresultsofaphase1bstudyofthesafetyandefficacyofthepi3kdinhibitoracalisibgs9820inrelapsedrefractorylymphoidmalignancies AT adewoyeadeboyehenry finalresultsofaphase1bstudyofthesafetyandefficacyofthepi3kdinhibitoracalisibgs9820inrelapsedrefractorylymphoidmalignancies AT gaojie finalresultsofaphase1bstudyofthesafetyandefficacyofthepi3kdinhibitoracalisibgs9820inrelapsedrefractorylymphoidmalignancies AT dreilinglyndah finalresultsofaphase1bstudyofthesafetyandefficacyofthepi3kdinhibitoracalisibgs9820inrelapsedrefractorylymphoidmalignancies AT xinyan finalresultsofaphase1bstudyofthesafetyandefficacyofthepi3kdinhibitoracalisibgs9820inrelapsedrefractorylymphoidmalignancies AT doorduijnjeanettek finalresultsofaphase1bstudyofthesafetyandefficacyofthepi3kdinhibitoracalisibgs9820inrelapsedrefractorylymphoidmalignancies AT kerstenmariejose finalresultsofaphase1bstudyofthesafetyandefficacyofthepi3kdinhibitoracalisibgs9820inrelapsedrefractorylymphoidmalignancies AT finalresultsofaphase1bstudyofthesafetyandefficacyofthepi3kdinhibitoracalisibgs9820inrelapsedrefractorylymphoidmalignancies |